Скачать с ютуб Anemia, bilirubin, and LDH identified as indicators of an increased mortality risk in CAD в хорошем качестве

Anemia, bilirubin, and LDH identified as indicators of an increased mortality risk in CAD

Catherine Broome, MD, Georgetown University Hospital, Washington, D.C, highlights findings from a study that used real-world data from the OPTUM electronic health record database to compare the mortality of patients with cold agglutinin disease (CAD) to the non-CAD population, and identify informative CAD biomarkers. This study demonstrated that patients with CAD indeed showed higher mortality risk compared to matched non-CAD patients. Moreover, anemia - and to a lesser extent bilirubin and LDH - could predict an increase in mortality or thromboembolic disease risk. Taken together, Dr Broome stresses that bilirubin, LDH, and anemia should be monitored and managed in patients with CAD to improve patient outcomes. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.